Olema Oncology Announces Expansion of Collaboration Agreement with Novartis
10 oct. 2023 07h00 HE
|
Olema Oncology
Amended clinical collaboration and supply agreement increases the palazestrant/ribociclib combination Phase 1/2 clinical study size to approximately 60 patients Expanded study supports the potential...
Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
22 sept. 2023 07h00 HE
|
Arch Biopartners
TORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that it has submitted applications to the Ministry of...
First-to-Market Edge for Apellis’s Syfovre in Geographic Atrophy Diminished in the Face of an Unexpected Safety Signal
28 juil. 2023 12h26 HE
|
Spherix Global Insights
Exton, Pennsylvania, July 28, 2023 (GLOBE NEWSWIRE) -- For many who have been following the retina market, the news about the emerging safety signal associated with Apellis’ Syfovre in geographic...
Drug Discovery Market Revenues to Reach USD 129.21 billion by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
28 juil. 2023 09h30 HE
|
Mordor Intelligence
Hyderabad, July 28, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled “Drug Discovery Market Report (2023-2028),” the market is estimated at USD 93.91 billion in 2023. It is...
Market Access Issues Hindering Specialists’ Use of Advanced Systemics in Lupus Nephritis
27 juil. 2023 16h00 HE
|
Spherix Global Insights
Exton, Pennsylvania, July 27, 2023 (GLOBE NEWSWIRE) -- While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and nephrologists with...
Florida Cancer Specialists & Research Institute First in Palm Beach County To Offer Targeted Radioligand Therapy for Metastatic Prostate Cancer
12 oct. 2022 13h40 HE
|
Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute locations in Palm Beach County are now offering Pluvicto ™, the first targeted radioligand...
Bragar Eagel & Squire, P.C. Is Investigating Novartis, Ebix, Intuit, and Argo and Encourages Investors to Contact the Firm
20 juil. 2022 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, July 20, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Novartis AG (NYSE: NVS),...
Bragar Eagel & Squire, P.C. Is Investigating Digital World, Generac, Novartis, and Cognyte and Encourages Investors to Contact the Firm
15 juil. 2022 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Digital World Acquisition...
Bragar Eagel & Squire, P.C. Is Investigating the WWE, Digital World, Generac, and Novartis and Encourages Investors to Contact the Firm
10 juil. 2022 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, July 10, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against World Wrestling...
Bragar Eagel & Squire, P.C. Is Investigating Novartis, Unity Software, Gap, and Cassava and Encourages Investors to Contact the Firm
04 juil. 2022 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, July 04, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Novartis AG (NYSE: NVS),...